Zobrazeno 1 - 10
of 67
pro vyhledávání: '"Luke Mitcheson"'
Autor:
Elizabeth Hughes, Jane Harris, Tom Ainscough, Angela Bate, Alex Copello, Sonia Dalkin, Gail Gilchrist, Emma Griffith, Lisa Jones, Michelle Maden, Luke Mitcheson, Harry Sumnall, Charlotte Walker
Publikováno v:
Health Technology Assessment, Vol 28, Iss 67 (2024)
Background People with severe mental illness who experience co-occurring substance use experience poor outcome including suicide, violence, relapses and use of crisis services. They struggle to access care and treatment due to a lack of an integrated
Externí odkaz:
https://doaj.org/article/e4f2ce82b88d42428c85b4b36d2bad22
Autor:
John Marsden, Mike Kelleher, Eilish Gilvarry, Luke Mitcheson, Jatinder Bisla, Angela Cape, Fiona Cowden, Edward Day, Jonathan Dewhurst, Rachel Evans, Will Hardy, Andrea Hearn, Joanna Kelly, Natalie Lowry, Martin McCusker, Caroline Murphy, Robert Murray, Tracey Myton, Sophie Quarshie, Rob Vanderwaal, April Wareham, Dyfrig Hughes, Zoë Hoare
Publikováno v:
EClinicalMedicine, Vol 66, Iss , Pp 102311- (2023)
Summary: Background: Daily methadone maintenance or buprenorphine treatment is the standard-of-care (SoC) medication for opioid use disorder (OUD). Subcutaneously injected, extended-release buprenorphine (BUP-XR) may be more effective—but there has
Externí odkaz:
https://doaj.org/article/74984ad835324f68b7da701787e3a009
Autor:
John Marsden, Mike Kelleher, Zoë Hoare, Dyfrig Hughes, Jatinder Bisla, Angela Cape, Fiona Cowden, Edward Day, Jonathan Dewhurst, Rachel Evans, Andrea Hearn, Joanna Kelly, Natalie Lowry, Martin McCusker, Caroline Murphy, Robert Murray, Tracey Myton, Sophie Quarshie, Gemma Scott, Sophie Turner, Rob Vanderwaal, April Wareham, Eilish Gilvarry, Luke Mitcheson
Publikováno v:
Trials, Vol 23, Iss 1, Pp 1-19 (2022)
Abstract Background Sublingual tablet buprenorphine (BUP-SL) and oral liquid methadone (MET) are the daily, standard-of-care (SOC) opioid agonist treatment medications for opioid use disorder (OUD). A sizable proportion of the OUD treatment populatio
Externí odkaz:
https://doaj.org/article/c1de5f4dc8184921b4e125d09f8a1f10
Autor:
Luke Mitcheson, John Marsden, Natalie Lowry, Mike Kelleher, Gemma Scott, Sophie Turner, Annette Hodge, Waniya Ashraf, Katie McClean
Publikováno v:
BMJ Open, Vol 13, Iss 3 (2023)
Objectives During the COVID-19 pandemic, addiction treatment services received official guidance asking them to limit face-to-face contact with patients and to prescribe opioid agonist treatment (OAT) medication flexibly. With the aim for most patien
Externí odkaz:
https://doaj.org/article/07add96d69fb4819ba02cd342aaf3196
Autor:
Eilish Gilvarry, Luke Mitcheson, Edward Day, John Marsden, Natalie Lowry, Fiona Cowden, Stacey Johnstone, Robbie Murray, Mike Kelleher
Publikováno v:
BMJ Open, Vol 12, Iss 10 (2022)
Introduction Opioid use disorder (OUD) is a debilitating and persistent disorder. The standard-of-care treatment is daily maintenance dosing of sublingual buprenorphine (BUP-SL) or oral methadone (MET). Monthly, extended-release, subcutaneous injecta
Externí odkaz:
https://doaj.org/article/9fc6ae523fc247d1b3abc69316411e11
Autor:
Julian Mutz, Andrew Pickles, Sarah Byford, John Dunn, Kimberley Goldsmith, Franziska Mosler, Tim Weaver, James Shearer, Emily Finch, John Strang, Clare Davey, Stephen Pilling, Anthony Glasper, Nicola Metrebian, Jennifer Hellier, Luke Mitcheson, Prun Bijral, Nadine Bogdan, Owen Bowden-Jones, Edward Day, Sam Forshall, Shabana Akhtar, Jalpa Bajaria, Carmel Bennett, Elizabeth Bishop, Vikki Charles, Roopal Desai, Claire Goodfellow, Farjana Haque, Nicholas Little, Hortencia McKechnie, Jo Morris, Ruth Pauli, Dilkushi Poovendran, Elizabeth Phillips
Publikováno v:
BMJ Open, Vol 11, Iss 7 (2021)
Introduction Most individuals treated for heroin use disorder receive opioid agonist treatment (OAT)(methadone or buprenorphine). However, OAT is associated with high attrition and persistent, occasional heroin use. There is some evidence for the eff
Externí odkaz:
https://doaj.org/article/f24202eeadc04da7b5c9163f933b9aae
Autor:
John Marsden, Camille Goetz, Tim Meynen, Luke Mitcheson, Garry Stillwell, Brian Eastwood, John Strang, Nick Grey
Publikováno v:
EBioMedicine, Vol 29, Iss , Pp 177-189 (2018)
Background: Cocaine use disorder (CUD) is a debilitating condition with no NICE-recommended medication or specific psychosocial interventions. In the United Kingdom (UK), general counselling (treatment-as-usual; TAU) is widely delivered, but has limi
Externí odkaz:
https://doaj.org/article/3c6140ae26d14fe19c3ea8b18f260650
Autor:
John Marsden, Camille Goetz, Tim Meynen, Luke Mitcheson, Garry Stillwell, Brian Eastwood, John Strang, Nick Grey
Publikováno v:
Contemporary Clinical Trials Communications, Vol 8, Iss C, Pp 264-273 (2017)
Introduction: Cocaine use disorder (CUD) is a debilitating condition characterised by maladaptive cocaine-related memories and impaired cognitive and behavioural control. There are no evidence-supported pharmacotherapies and only weakly effective psy
Externí odkaz:
https://doaj.org/article/da7eadb3dc8640ea99f50cd5e92af897
Autor:
Lucas Wiessing, Marica Ferri, Vendula Běláčková, Patrizia Carrieri, Samuel R. Friedman, Cinta Folch, Kate Dolan, Brian Galvin, Peter Vickerman, Jeffrey V. Lazarus, Viktor Mravčík, Mirjam Kretzschmar, Vana Sypsa, Ana Sarasa-Renedo, Anneli Uusküla, Dimitrios Paraskevis, Luis Mendão, Diana Rossi, Nadine van Gelder, Luke Mitcheson, Letizia Paoli, Cristina Diaz Gomez, Maitena Milhet, Nicoleta Dascalu, Jonathan Knight, Gordon Hay, Eleni Kalamara, Roland Simon, EUBEST working group, Catherine Comiskey, Carla Rossi, Paul Griffiths
Publikováno v:
Harm Reduction Journal, Vol 14, Iss 1, Pp 1-14 (2017)
Abstract Background and aims Despite advances in our knowledge of effective services for people who use drugs over the last decades globally, coverage remains poor in most countries, while quality is often unknown. This paper aims to discuss the hist
Externí odkaz:
https://doaj.org/article/e09ff1444d4542e8ae72fb94c7c8369d
Autor:
Camille Goetz, Tim Meynen, Luke Mitcheson, Nick Grey, Brian Eastwood, John Strang, John Marsden
Publikováno v:
Journal of Experimental Psychopathology, Vol 10 (2019)
Cocaine use disorder (CUD) is a debilitating psychopathology, with no recommended medication therapy or specific psychological intervention. Memory-focused cognitive therapy (MFCT) is a novel psychotherapy for CUD, theorized to modify and reconsolida
Externí odkaz:
https://doaj.org/article/b807919e0d2d4a2a8100305848b1e79c